Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mendelian randomization and clinical trial evidence supports TYK2 inhibition as a therapeutic target for autoimmune diseases.

EBioMedicine - 1 Mar 2023

Yuan Shuai, Wang Lijuan, Zhang Han, Xu Fengzhe, Zhou Xuan, Yu Lili, Sun Jing, Chen Jie, Ying Haochao, Xu Xiaolin, Yu Yongfu, Spiliopoulou Athina, Shen Xia, Wilson Jim, Gill Dipender, Theodoratou Evropi, Larsson Susanna C, Li Xue

Abstract excerpt

BACKGROUND: To explore the associations of genetically proxied TYK2 inhibition with a wide range of disease outcomes and biomarkers to identify therapeutic repurposing opportunities, adverse effects, and biomarkers of efficacy. METHODS: The loss-of-function missense variant rs34536443 in TYK2 gene was used as a genetic instrument to proxy the effect of TYK2 inhibition. A phenome-wide Mendelian randomization (MR)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoimmune Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers

Share to Genome-Wide Association Study

Share to Mendelian Randomization Analysis

Share to Polymorphism, Single Nucleotide

Share to Psoriasis

Share to TYK2 Kinase

Source

Open in PubMed Open full text

Identifiers

PMID: 36842216
DOI: 10.1016/j.ebiom.2023.104488
PMCID: PMC9988426

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mendelian randomization and clinical trial evidence supports TYK2 inhibition as a therapeutic target for autoimmune diseases.PMID 36842216Read ↗

Validation of TYK2 and exploration of PRSS36 as drug targets for psoriasis using Mendelian randomization.Semantic proximity Read ↗

Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity.Semantic proximity Read ↗

Germline TYK2 mutation and cancer riskSemantic proximity Read ↗

Meta-analysis of TYK2 gene polymorphisms association with susceptibility to autoimmune and inflammatory diseases.Semantic proximity Read ↗

Characterising a Novel Therapeutic Target for Psoriasis, TYK2, Using Functional Genomics.Semantic proximity Read ↗

Genetic evidence for efficacy of targeting IL-2, IL-6, and TYK2 signaling in prevention of type 1 diabetes: A Mendelian randomization studySemantic proximity Read ↗

TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits.Semantic proximity Read ↗

Genetic evidence for efficacy of targeting IL-2, IL-6 and TYK2 signalling in the prevention of type 1 diabetes: a Mendelian randomisation study.Semantic proximity Read ↗

Genetically proxied TYK2 inhibition is associated with reduced sarcoidosis susceptibility.Semantic proximity Read ↗

Immune Cell-Based Transcriptomic Mendelian Randomization and Colocalization Study on Type 1 DiabetesSemantic proximity Read ↗

Tyk2 Targeting in Immune-Mediated Inflammatory DiseasesSemantic proximity Read ↗

Integrative multi-omics Mendelian randomization and functional validation identifies RNASET2 as a novel therapeutic target for autoimmune thyroiditis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.